Biomarkers predictive of predisposition to depression and response to treatment

• US 10,233,501 B2
• Filed: 10/06/2017
• Issued: 03/19/2019
• Est. Priority Date: 10/19/2010
• Status: Active Grant

• Current Assignee: Northwestern University
• Original Assignee: Northwestern University
• Inventors: Redei, Eva E.
• Primary Examiner(s): Haney, Amanda
• Application Number:
  US15/727,174
• Publication Number:
  US 20180030538A1
• Time in Patent Office: 529 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2800/304 Mood disorders, e.g. bipolar, depression
• CPC Class Codes: G01N 2800/60 Complex ways of combining multiple protein biomarkers for diagnosis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject'"'"'s responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.

Claims

1. A panel of biomarkers consisting of an isolated set of 100 or fewer full-length cDNA biomarkers, wherein said isolated set includes DGKA, RAPH1, and KIAA1539 full-length cDNA biomarkers.

2. The panel of biomarkers of claim 1, comprising a full-length DRD2 cDNA biomarker.

3. The panel of biomarkers of claim 1, comprising a full-length OSBPL2 cDNA biomarker.

4. The panel of biomarkers of claim 1, comprising a full-length DAG1 cDNA biomarker.

5. The panel of biomarkers of claim 1, comprising a full-length OTX2 cDNA biomarker.

6. The panel of biomarkers of claim 1, comprising a full-length DPPA3 cDNA biomarker.

7. The panel of biomarkers of claim 1, comprising a full-length RAB27B cDNA biomarker.

8. The panel of biomarkers of claim 1, a full-length CTTNBP2 cDNA biomarker.

9. The panel of biomarkers of claim 1, comprising a full-length LIX1 cDNA biomarker.

10. The panel of biomarkers of claim 1, comprising a full-length NTRK2 cDNA biomarker.

11. The panel of biomarkers of claim 1, comprising a full-length SLC24A4 cDNA biomarker.

12. The panel of biomarkers of claim 1, comprising a full-length MARCKS cDNA biomarker.

13. The panel of biomarkers of claim 1, comprising a full-length ASAH1 cDNA biomarker.

14. The panel of biomarkers of claim 1, comprising a full-length ATP11C cDNA biomarker.

15. The panel of biomarkers of claim 1, comprising a full-length PSME1 cDNA biomarker.

16. The panel of biomarkers of claim 1, comprising a full-length IGSF4A cDNA biomarker.

17. The panel of biomarkers of claim 1, comprising a full-length ADCY3 cDNA biomarker.

18. The panel of biomarkers of claim 1, comprising full-length FAM46A cDNA biomarker.